Endocrine System and Metabolic Diseases
The endocrine system plays a crucial role in maintaining homeostasis within the human body. It consists of various glands that secrete hormones, which act as chemical messengers to regulate bodily functions. When the endocrine system malfunctions, it can lead to metabolic diseases. Our company is a leading provider of drug and therapy development services for endocrine system and metabolic diseases.
Overview of Endocrine System and Metabolic Diseases
Endocrine system and metabolic diseases refer to a group of disorders that arise from abnormalities in hormone production, regulation, or utilization, leading to disruptions in metabolism and overall bodily functions. The endocrine system includes glands such as the pituitary, thyroid, adrenal, and pancreas, among others. These glands secrete hormones that travel through the bloodstream and act on target tissues or organs to regulate processes such as metabolism, growth, reproduction, and development.
Metabolic diseases, often associated with endocrine disorders, involve abnormalities in energy production, storage, and utilization. Some common metabolic diseases include diabetes, obesity, metabolic syndrome, and certain genetic disorders like phenylketonuria.
Pathogenesis of Endocrine System and Metabolic Diseases
- Genetic mutations or defects in the genes responsible for hormone production or receptor function can contribute to endocrine disorders.
- Certain medical conditions, such as infections, autoimmune disorders, or tumors affecting endocrine glands, can also cause endocrine system and metabolic diseases.
- Environmental factors, such as exposure to toxins or certain medications, may also disrupt hormone balance.
- Lifestyle factors such as poor diet, sedentary behavior, and stress can contribute to the development of metabolic diseases like obesity and type 2 diabetes.
Fig.1 Schematic overview of endpoints of diseases affected by Endocrine Disrupting Chemicals (EDCs). (Ahn, Changhwan, et al., 2023)Therapeutic Strategies of Endocrine System and Metabolic Diseases
| Indication | Related Drugs |
|---|---|
| Alpha-1-Antitrypsin Deficiency | Dimercaprol and Protein C |
| Alpha-mannosidosis | Sorbitol and Glycine |
| Fabry Disease | Coal tar and Dapagliflozin |
| Gaucher Disease, Type Iii | Eliglustat and Enzyme Inhibitors |
| Growth Hormone Deficiency | Tesamorelin and Liraglutide |
| Wilson Disease | Zinc cation and Molybdenum |
| Carcinoid Syndrome | Pasireotide and Cyproheptadine |
Therapy Development for Endocrine System and Metabolic Diseases
Hormone Replacement Therapy
In cases of hormone deficiency, replacing the deficient hormone can restore balance and alleviate symptoms. This approach is commonly used in conditions like hypothyroidism or hormone deficiencies in the reproductive system.
Medication to Modify Hormone Activity
Certain medications can modify hormone activity, either by stimulating or inhibiting hormone production or receptor activity. Examples include anti-diabetic medications, growth hormone receptor antagonists, or medications to regulate adrenal hormone production.
Our Services
Our team of experts is dedicated to providing our clients with high-quality diagnostics and therapeutics development services that advance our clients' understanding of and development of therapies for endocrine and metabolic diseases.
Rare Types of Endocrine System and Metabolic Diseases
| A-G | |
| Acromegaly | Alpha-1 Antitrypsin Deficiency (A1AD) |
| Allan-Herndon-Dudley Syndrome (AHDS) | Alpha-Mannosidosis (AM) |
| Argininosuccinic aciduria (ARGINSA) | Conn's Syndrome |
| Crigler-Najjar Syndrome (CN1) | Fabry Disease (FD) |
| Gaucher Disease (GD) | Glycogen Storage Disease Type Ia (GSDIa) |
| Glycogen Storage Disease Type III (GSDIII) | Growth Hormone Deficiency (GHD) |
| H-L | |
| Homozygous Familial Hypercholesterolemia (HoFH) | Hyperprolactinemia (HPRL) |
| Hyperparathyroidism | Inborn Errors of Metabolism (IEM) |
| Inherited Metabolic Disorder (IMD) | Lesch-Nyhan Syndrome (LNS) |
| Leber’s Hereditary Optic Neuropathy (LHON) | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) |
| Lysosomal Acid Lipase Deficiency (CESD) (Wolman disease) | |
| M-O | |
| Maple Syrup Urine Disease (MSUD) | Metachromatic Leukodystrophy (MLD) |
| Menkes Disease (MNK) | Methylmalonic Acidemia (MMA) |
| Mitochondrial DNA depletion Syndrome (MDS) | Mucopolysaccharidosis (MPS) |
| Mucolipidosis | Niemann-Pick Disease (NPD) |
| Ornithine Transcarbamylase Deficiency (OTCD) | Ornithine Transcarbamylase Deficiency (OTCD) |
| P-X | |
| Pompe Disease (PD) | Propionic Acidemia (PA1) |
| Prader-Willi Syndrome (PWS) | Pseudohypoaldosteronism Type 1 (PHA1) |
| Sandhoff Disease (GM2G2) | Tangier Disease (TGD) |
| Smith-Magenis Syndrome (SMS) | Tumor-Induced Osteomalacia (TIO) |
| Urea Cycle Disorder (UCD) | X-Linked Hypophosphatemia (XLH) |
| Wilson Disease (WD) | |
Therapy Development Platforms
Animal models play an important role in the study of the mechanisms of rare diseases and the evaluation of drug development. Our company provides comprehensive disease modeling, drug safety evaluation, and pharmacokinetic analysis services for a wide range of rare metabolic diseases such as lysosomal storage diseases (LSDs) and glycogen storage diseases using the most advanced technologies and best practices in the field.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Ahn, Changhwan, and Eui-Bae Jeung. "Endocrine-disrupting chemicals and disease endpoints." International Journal of Molecular Sciences 24.6 (2023): 5342.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.